A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview We are a company that provides esoteric molecular diagnostic testing, and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer from clinical features. We develop and commercialize genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. Customer Category Types of Customers Nature of Services Clinical services ● Hospitals ● Physicians ● Cancer Centers ● Clinics Clinical services that help guide patient management decisions by providing information on the diagnosis and prognosis of indeterminate specimens. Guidance on genetic marker-related pharmaceutical treatment options, when available, is also provided.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 42M | 47M | 40M | - | 41M | 32M |
| Net Income | 4.3M | 6.2M | 2.0M | -22M | -15M | -29M |
| EPS | $-0.40 | $0.40 | $0.45 | $-5.18 | $-3.61 | $-7.32 |
| Free Cash Flow | 0 | 3.8M | 3.3M | -8.0M | -9.1M | -16M |
| ROIC | 46.4% | 58.1% | 27.0% | -13.3% | -36.4% | -57.1% |
| Gross Margin | 64.6% | 63.8% | 62.6% | - | 45.5% | 33.1% |
| Debt/Equity | 0.00 | -2.92 | -0.14 | -0.11 | -0.16 | -0.43 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 5.6M | 8.1M | 4.0M | -3.6M | -14M | -26M |
| Operating Margin | 13.3% | 17.3% | 9.9% | - | -33.9% | -80.5% |
| ROE | 0.0% | - | - | - | - | - |
| Shares Outstanding | 4M | 4M | 4M | 4M | 4M | 4M |
INTERPACE BIOSCIENCES, INC. passes 3 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 51.2%. Total shareholder yield (buybacks) is 0.5%. At current prices, the estimated annualized return to fair value is -29.8%.
INTERPACE BIOSCIENCES, INC. (IDXG) has a 5-year average return on invested capital (ROIC) of -4.3%. This is below average and may indicate limited pricing power.
INTERPACE BIOSCIENCES, INC. (IDXG) has a market capitalization of $10M. It is classified as a small-cap stock.
INTERPACE BIOSCIENCES, INC. (IDXG) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.47%.
INTERPACE BIOSCIENCES, INC. (IDXG) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
INTERPACE BIOSCIENCES, INC. (IDXG) reported annual revenue of $47 million in its most recent fiscal year, based on SEC EDGAR filings.
INTERPACE BIOSCIENCES, INC. (IDXG) has a net profit margin of 13.3%. This is a healthy margin.
INTERPACE BIOSCIENCES, INC. (IDXG) generated $4 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
INTERPACE BIOSCIENCES, INC. (IDXG) reported earnings per share (EPS) of $0.40 in its most recent fiscal year.
INTERPACE BIOSCIENCES, INC. (IDXG) has a 5-year average gross margin of 51.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for INTERPACE BIOSCIENCES, INC. (IDXG), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
INTERPACE BIOSCIENCES, INC. (IDXG) has a book value per share of $-0.50, based on its most recent annual SEC filing.